Ken Griffin
CCCC icon

Ken Griffin’s C4 Therapeutics CCCC Stock Holding History

Ken Griffin’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$88.4K Sell
33,600
-5,100
-13% -$12K ﹤0.01% 12121
2025
Q4 		$73.9K Sell
38,700
-15,700
-29% -$37.2K ﹤0.01% 11843
2025
Q3 		$121K Buy
+54,400
New +$131K ﹤0.01% 11702
2025
Q1 		– Sell
-103,100
Closed -$371K – 14554
2024
Q4 		$371K Buy
103,100
+84,400
+451% +$420K ﹤0.01% 9225
2024
Q3 		$107K Sell
18,700
-90,300
-83% -$543K ﹤0.01% 11022
2024
Q2 		$504K Sell
109,000
-45,500
-29% -$271K ﹤0.01% 8032
2024
Q1 		$1.26M Sell
154,500
-58,400
-27% -$453K ﹤0.01% 6455
2023
Q4 		$1.2M Buy
212,900
+197,200
+1,256% +$450K ﹤0.01% 6320
2023
Q3 		$29.2K Buy
15,700
+13,800
+726% +$42.1K ﹤0.01% 12290
2023
Q2 		$5.22K Sell
1,900
-600
-24% -$1.93K ﹤0.01% 13523
2023
Q1 		$7.85K Sell
2,500
-1,000
-29% -$5.89K ﹤0.01% 13695
2022
Q4 		$20.6K Buy
+3,500
New +$29K ﹤0.01% 13121
2022
Q2 		– Sell
-14,200
Closed -$344K – 12958
2022
Q1 		$344K Buy
+14,200
New +$345K ﹤0.01% 10277

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ken Griffin's CCCC Position: Q1 2026 in Review

Ken Griffin increased its C4 Therapeutics (CCCC) stake by 461% in Q1 2026, buying an estimated $4.86M and bringing the position to 2,511,015 shares worth $6.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3893.

Ken Griffin first reported a position in CCCC in Q4 2020 and has held it in 20 quarters since. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Ken Griffin held 2,511,015 shares of C4 Therapeutics worth $6.6M as of Q1 2026.
  • Ken Griffin bought 2,063,207 C4 Therapeutics shares in Q1 2026, an estimated $4.86M.
  • C4 Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #3893 holding.
  • Ken Griffin first reported a position in C4 Therapeutics in Q4 2020 and has held it in 20 quarters since.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.